Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1993-07-06
1995-09-05
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
514783, 514815, 514822, 514834, A61K 3578
Patent
active
054477204
ABSTRACT:
A composition and method of treatment of hemoglobinopathies, such as, for example, sickle cell disease and thalassemia, wherein an inventive extract used in such treatment is obtained from alfalfa and other certain plant materials, preferably using a hydroxide base and hexane. In the most preferred embodiment, the plant material is first extracted with 1,1,1-trichloroethane and a hydroxide base, followed by extraction with hexane. The polar acidic compounds present in alfalfa and other plant materials selectively dissolve in the hexane phase and exhibit good antisickling activity in vitro. Further, these active compounds which comprise the inventive extract are effective in vivo by significantly alleviating the many clinical manifestations of sickle cell disease and thalassemia experienced by the affected patients.
REFERENCES:
patent: 3102891 (1963-09-01), Allen
patent: 4473559 (1984-09-01), Robinson
Adekile, Adeodu, Fadulu, Weinhemer, and Sanduja, Preliminary Clinical Trial of Nix-06999 in the Management of Sickle Cell Anemia, vol. 20, No. 1, Nigerian Medical Journal (Jan.-Mar. 1990).
Adekile, Adeodu, and Fadulu, Preliminary Clinical Trial of NX-06999 in the Management of Sickle Cell Anemia, Dept. of Pediatrics and Chile Health, Faculty of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria, Dept. of Biology, Texas Southern University, Tex.
Fadulu, Ethyl-Alcohol Extract from Fagara Zanthoxyloides Root: Invitro Effect on Red Blood Cells, Faculty Research Journal, pp. 22-31, Texas Southern University.
Grant Application to the Department of Health and Human Services, Public Health Service, entitled "A New Drug for Sickle Cell Disease," Feb. 18, 1992.
Sofowora, Isaac-Sodeye, and Ogunkoya, Isolation and Characteristics of an Antisickling Agent from Fagara zanthoxyloides Root, vol. 38, No. 2, Lloydia, pp. 169-171 (Mar.-Apr. 1975).
Honig, Farnsworth, Ferenc, and Vida, Evaluation of Fagara zanthoxyloides Root Extract in Sickle Cell Anemia Blood in Vitro, vol. 38, No. 5, Lloydia, pp. 387-390 (Sep.-Oct. 1975).
Fadulu, Translating African Medicine into Western Techno-scientific Concepts, vol. 1, An International Journal of Traditional medicine, pp. 134-138 (1990).
Jones, Sandra Dianne, The Effects of Fagara Zanthoxyloides (An Anti-Sickling Agent) on the Sickle Cell Membrane (unpublished M.S. thesis, Texas Southern University (1979).
Somerville, Barry C., Mechanism of an Antisickling Agent: Effect on the Concentration of 2, 3 DPG in Sickle Cell Anemia, Sickle Cell trait and Normal Hemoglobin (unpublished M.S. thesis, Texas Southern University (1978).
Enigbokan, Mofolurunso A., The Role of an Extract of Fagara Zanthoxyloides in the Inhibition of Dental Caries (unpublished M.S. thesis, Texas Southern University) (1978).
Ekong, et al, New Antisickling agent 3,4-dihydro-2,2-dimethyl-2H-1 benzopyran-6-butyric acid, vol. 258, Nature, pp. 743-746 (1975).
Fadulu Sunday O.
Lee Howard C.
Okorafor James O.
Robinson Douglas W.
LandOfFree
Composition and method for treatment of hemoglobinopathies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for treatment of hemoglobinopathies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for treatment of hemoglobinopathies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-471186